Genmab A/S EBITDA per Employee
The EBITDA per Employee of Genmab A/S (GMAB.CO) as of Sep 27, 2026 is 437,159.08 USD. In the previous year, EBITDA per Employee was 1.93 M USD — a change of -77.40% (lower).
Get this data via API
Financial Data API
EBITDA per Employee
437,159.08USD
YoY
-77.40%
Last updated:
The Genmab A/S EBITDA per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA per Employee | YoY |
|---|---|---|
| 437,159.08USD | -77.40% | |
| 1.93 MUSD | +34.74% | |
| 1.44 MUSD | -15.44% | |
| 1.70 MUSD | +115.59% | |
| 787,660.28USD | -54.45% | |
| 1.73 MUSD | +135.14% | |
| 735,460.59USD | +88.60% | |
| 389,957.96USD | +5.72% | |
| 368,857.79USD | +27.34% | |
| 289,671.30USD | +44.46% | |
| 200,524.53USD | +170.61% | |
| 74,101.32USD | — |
Genmab A/S Stock analysis
Frequently Asked Questions about Genmab A/S stock
EBITDA per Employee of Genmab A/S is 437,159.08 USD in 2026.
EBITDA per Employee of Genmab A/S changed from 1.93 M USD to 437,159.08 USD, representing a -77.40% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Employee Genmab A/S since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Genmab A/S historically and in real time.
Workforce — Genmab A/S
All Key Metrics — Genmab A/S
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth